Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
NCT04752813 · View on ClinicalTrials.gov ↗
Study Summary
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG Temozolomide (TMZ)
- DRUG BPM31510
- OTHER Vitamin K1
Study Locations (11)
California
- Cedars-Sinai Medical Center — Los Angeles
- Stanford University Cancer Center — Palo Alto
- Sansum Clinic — Santa Barbara
Virginia
- Virginia Cancer Specialists — Fairfax
- Inova — Fairfax
- Virginia Oncology Associates — Norfolk
Texas
- Texas Oncology — Austin
- UT Health San Antonio Mays Cancer Center — San Antonio
Massachusetts
- Dana Farber Cancer Institute — Boston
New Jersey
- Valley Health — Ridgewood
New York
- Mount Sinai Hospital — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2030-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752813
The ClinicalTrials.gov registry entry for NCT04752813 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BPGbio, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions — of which Radiation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04752813 reports 11 study locations spanning 6 distinct geographic areas — top geographies include California, Virginia, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04752813 about?
NCT04752813 is a clinical study titled "A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)". This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
What is the current status of trial NCT04752813?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-08-22. Estimated completion is 2030-08-26.
What conditions does trial NCT04752813 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04752813?
The interventions under investigation include: Radiation (RADIATION), Temozolomide (TMZ) (DRUG), BPM31510 (DRUG), Vitamin K1 (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04752813?
This trial is sponsored by BPGbio, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04752813 being conducted?
This trial has 11 study locations across California, Massachusetts, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.